Newron Pharmaceuticals SpA (CHIX:NWRNZ) Short Percentage of Float


CHIX:NWRNZ Newron Pharmaceuticals SpA CHIX:NWRNZ
48 GF Score
Price CHF12.62
GF Value CHF12.89
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CHIX:NWRNZ vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Newron Pharmaceuticals SpA Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Newron Pharmaceuticals SpA's Short Percentage of Float falls into.


CHIX:NWRNZ
48GF Score
Newron Pharmaceuticals SpA CHIX:NWRNZ
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Newron Pharmaceuticals SpA (CHIX:NWRNZ) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of CHF12.62 is trading 2.1% below its estimated GF Value™ of CHF12.89. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for CHIX:NWRNZ:

  • Short Percentage of Float:
  • GF Value™: CHF12.89 vs. price of CHF12.62 (2.1% below fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the CHIX:NWRNZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
48GF Score

Get the complete analysis for CHIX:NWRNZ

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF12.62
Price
CHF12.89
GF Value